Cyrano was founded by Ira Sanders, M.D., a board certified Otolaryngologist who
began experimenting with botulinum toxin for rhinitis in 1992. He was a faculty member
at the Mount Sinai School of Medicine for 15 years where he performed award
winning research funded by five major grants from the National Institutes of Health.
He has 7 awarded patents, two of whichhave been successfully commercialized.
Within the past five years, he has founded three companies which have
successfully attracted angel and venture capital, as well as NIH and NJ
research grant funding.
Shawn O'Brien, the former CEO of one of the few companies producing FDA
approved botulinum toxin provides executive leadership.
Mark Funston, the former CFO of Medscape/WebMD advises on finance issues.
Operations and Administration
Alex Paris, a student at the Wharton School of Business, wrote the initial business
plan and continues to provide organizational and strategic advice.
Asif Amirali, M.D., has ten years experience in research and medical based
Regulatory Affairs and Clinical Trials
Marilyn R. Carlson, D.M.D., M.D., RAC, President of Entremedica Inc,
consults on clinical and regulatory issues.
Joseph F. Sgherza has over 20 years of experience in conducting clinical trials all
over the world.
Medical and Scientific Advisors
Andrew Blitzer, M.D., D.D.S., F.A.C.S. is an internationally known Otolaryngologist
and pioneer in the use of botulinum toxin in medicine. He is perhaps the only
American physician to have performed a clinical trial of botulinum toxin for rhinitis.
Peter Catalano, M.D., F.A.C.S. is Chairman of Otolaryngology at St Elizabeth's
Hospital in Boston. Dr Catalano has extensive experience in using botulinum toxin to treat rhinitis.